JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Identification of a novel ADCC-related gene signature for predicting the prognosis and therapy response in lung adenocarcinoma

  • 0Department of Thoracic Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.] +

|

March 20, 2024

|

March 20, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a novel 16-gene prognostic signature for Antibody-Dependent Cellular Cytotoxicity (ADCC) in lung adenocarcinoma (LUAD). The ADCC score (ADCCRS) accurately predicts patient survival and treatment response, offering critical insights for LUAD management.

Area Of Science

  • Oncology
  • Immunology
  • Bioinformatics
  • Genomics

Background

  • The role of Antibody-Dependent Cellular Cytotoxicity (ADCC) in lung adenocarcinoma (LUAD) has been understudied.
  • No systematic compilation of ADCC-associated genes for prognostic signatures in LUAD exists.

Purpose Of The Study

  • To construct and validate a prognostic signature based on ADCC-associated genes for LUAD.
  • To evaluate the signature's predictive ability for patient survival and treatment response.
  • To explore the association of the signature with the tumor microenvironment and pan-cancer characteristics.

Main Methods

  • Utilized machine learning algorithms to construct a 16-gene ADCC score (ADCCRS) from LUAD, NSCLC, and diverse cancer cohorts.
  • Validated prognostic power across 28 independent datasets and compared it with existing signatures.
  • Integrated bulk and single-cell transcriptome data, analyzed copy number variations (CNV), single nucleotide variations (SNV), and predicted drug sensitivity and immunotherapy response.

Main Results

  • Identified two distinct LUAD subtypes with differential clinical characteristics.
  • The ADCCRS demonstrated superior predictive ability for LUAD patient survival compared to 102 previous signatures.
  • High ADCCRS correlated with increased gene mutation, specific tumor microenvironment (TME) modulators, and predicted sensitivity to chemotherapy/targeted therapy but resistance to immunotherapy.
  • ADCCRS showed significant prognostic value and acted as a risk factor across various cancer types.

Conclusions

  • The ADCCRS provides crucial prognostic insights for LUAD patients.
  • It aids in understanding the tumor microenvironment and predicting treatment responsiveness.
  • The signature holds potential for guiding clinical decisions in LUAD and other cancers.

Keywords: